Molecular Genetics of Ewing Sarcoma

Referencias bibliográficas

• Abaan OD, Levenson A, Khan O, et al. (2005) PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing’s sarcoma tumorigenesis. Oncogene 24: 2715–2722.
• Amaral, AT, Garofalo, C, Frapolli, R et al. (2015) Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. Clinical Cancer Research: PMID:25609059
• Amaral AT, Ordóñez JL, Otero-Motta AP, et al. (2014) Innovative therapies in Ewing sarcoma. Advances in Anatomic Pathology 21: 49–67.
• Amsellem V, Kryszke MH, Hervy M, et al. (2005) The actin cytoskeleton-associated protein zyxin acts as a tumor suppressorin Ewing tumor cells. Experimental Cell Research 304: 443–456.
• Arvand A, Bastians H, Welford SM, et al. (1998) EWS/FLI1 upregulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 17: 2039–2045.
• Boro A, Pretre K, Rechfeld F, et al. (2012) Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing’s sarcoma. International Journal of Cancer 131: 2153–2164.
• Bracken AP, Pasini D, Capra M, et al. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. The EMBO Journal 22: 5323–5335.
• Brenner JC, Feng FY, Han S, et al. (2012) PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Research 72: 1608–1613.
• Carrillo J, Garcia-Aragoncillo E, Azorin D, et al. (2007) Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clinical Cancer Research 13: 2429–2440.
• Cerisano V, Aalto Y, Perdichizzi S, et al. (2004) Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing’s sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 23: 5664–5674.
• Choy E, Butrynski JE, Harmon DC, et al. (2014) Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14: 813. Cironi L, Riggi N, Provero P, et al. (2008) IGF1 is a common target gene of Ewing’s sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 3: e2634.
• Cornaz-Buros S, Riggi N, DeVito C, et al. (2014) Targeting cancer stem-like cells as an approach to defeating cellular heterogeneity in Ewing sarcoma. Cancer Research 74: 6610–6622.
• Dauphinot L, De Oliveira C, Melot T, et al. (2001) Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 20: 3258–3265.
• De Vito C, Riggi N, Suva ML, et al. (2011) Let-7a is a direct EWS-FLI-1 target implicated in Ewing’s sarcoma development. PLoS One 6: e23592.
• De Vito C, Riggi N, Cornaz S, et al. (2012) A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell 21: 807–821.
• Delattre O, Zucman J, Plougastel B, et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162–165.
• Deneen B, Hamidi H and Denny CT (2003a) Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Research 63: 4268–4274.
• Deneen B, Welford SM, Ho T, et al. (2003b) PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Molecular and Cellular Biology 23: 3897–3908.
• Drake RR and Kislinger T (2014) The proteomics of prostate cancer exosomes. Expert Review of Proteomics 11: 167–177.
• DuBois SG, Krailo MD, Lessnick SL, et al. (2009) Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatric Blood & Cancer 52: 324–327.
• van der Ent W, Jochemsen AG, Teunisse AF, et al. (2014) Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. The Journal of Pathology 233: 415–424. Fuchs B, Inwards C, Scully SP and Janknecht R (2004) hTERT is highly expressed in Ewing’s sarcoma and activated by EWS-ETS oncoproteins. Clinical Orthopaedics and Related Research 64-68.
• Fukuma M, Okita H, Hata J and Umezawa A (2003) Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 22: 1–9.
• Garcia-Aragoncillo E, Carrillo J, Lalli E, et al. (2008) DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing’s tumor cells. Oncogene 27: 6034–6043. Garofalo C, Capristo M, Manara MC, et al. (2013) Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. PLoS One 8: e83832.
• Gazziola C, Cordani N, Carta S, et al. (2005) The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells. International Journal of Oncology 26: 129–140.
• Grohar PJ, Segars LE, Yeung C, et al. (2013) Dual targeting of EWS-FLI1 activity and the associated DNA damage response with Trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clinical Cancer Research 20: 1190–1203. Guan H, Zhou Z, Cao Y, et al. (2009) VEGF165 promotes the osteolytic bone destruction of Ewing’s sarcoma tumors by upregulating RANKL. Oncology Research 18: 117–125.
• Hahm KB, Cho K, Lee C, et al. (1999) Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nature Genetics 23: 222–227.
• Hauer K, Calzada-Wack J, Steiger K, et al. (2013) DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. Cancer Research 73: 967–977.
• Hayward DG, Clarke RB, Faragher AJ, et al. (2004) The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Research 64: 7370–7376.
• Herrero-Martin D, Osuna D, Ordóñez JL, et al. (2009) Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. British Journal of Cancer 101: 80–90.
• Hong SH, Youbi SE, Hong SP, et al. (2014) Pharmacokinetic modeling optimizes inhibition of the ‘undruggable’ EWS-FLI1 transcription factor in Ewing sarcoma. Oncotarget 5: 338–350.
• Ichikawa H, Shimizu K, Hayashi Y and Ohki M (1994) An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Research 54: 2865–2868.
• Im YH, Kim HT, Lee C, et al. (2000) EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Cancer Research 60: 1536–1540.
• Italiano A, Sung YS, Zhang L, et al. (2012) High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes, Chromosomes & Cancer 51: 207–218.
• Jeon IS, Davis JN, Braun BS, et al. (1995) A variant Ewing’s sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10: 1229–1234.
• Jiang X, Gwye Y, Russell D, et al. (2010) CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 10: 116.
• Jones FS and Jones PL (2000) The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Developmental Dynamics 218: 235–259.
• Kaneko Y, Yoshida K, Handa M, et al. (1996) Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes, Chromosomes & Cancer 15: 115–121.
• Kawamura-Saito M, Yamazaki Y, Kaneko K, et al. (2006) Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Human Molecular Genetics 15: 2125–2137.
• Kikuchi R, Murakami M, Sobue S, et al. (2007) Ewing’s sarcoma fusion protein, EWS/Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5′promoter. Oncogene 26: 1802–1810.
• Kovar H (2014) Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opinion on Therapeutic Targets 18: 1315–1328.
• Kovar H, Alonso J, Aman P, et al. (2012) The first European interdisciplinary ewing sarcoma research summit. Frontier in Oncology 2: 54.
• Le Deley MC, Delattre O, Schaefer KL, et al. (2010) Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. Journal of Clinical Oncology 28: 1982–1988.
• Lee Y, El Andaloussi S and Wood MJ (2012) Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Human Molecular Genetics 21: R125–R134.
• Leuchte K, Altvater B, Hoffschlag S, et al. (2014) Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. Oncology Reports 32: 845–852.
• MacKeigan JP, Murphy LO and Blenis J (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biology 7: 591–600.
• Mackintosh C, Ordóñez JL, Garcia-Dominguez DJ, et al. (2012) 1qgain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 31: 1287–1298.
• Mackintosh C, Garcia-Dominguez DJ, Ordóñez JL, et al. (2013) WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene 32: 1441–1451.
• Maire G, Brown CW, Bayani J, et al. (2008) Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review. Cancer Genetics and Cytogenetics 181: 81–92.
• Marques Howarth M, Simpson D, Ngok SP, et al. (2014) Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. The Journal of Clinical Investigation 124: 5275–5290.
• Martins AS, Mackintosh C, Martin DH, et al. (2006) Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clinical Cancer Research 12: 3532–3540.
• Martins AS, Ordóñez JL, Garcia-Sanchez A, et al. (2008) A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Research 68: 6260–6270.
• Mastrangelo T, Modena P, Tornielli S, et al. (2000) A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene 19: 3799–3804.
• Matsunobu T, Tanaka K, Nakamura T, et al. (2006) The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Research 66: 803–811.
• May WA, Arvand A, Thompson AD, et al. (1997) EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nature Genetics 17: 495–497.
• Mertens F, Wiebe T, Adlercreutz C, et al. (2007) Successful treatment of a child with t(15;19)-positive tumor. Pediatric Blood & Cancer 49: 1015–1017.
• Miller IV, Raposo G, Welsch U, et al. (2013) First identification of Ewing’s sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. Biology of the Cell 105: 289–303.
• Nakatani F, Tanaka K, Sakimura R, et al. (2003) Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. The Journal of Biological Chemistry 278: 15105–15115.
• Nazarenko I, Rana S, Baumann A, et al. (2010) Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Research 70: 1668–1678.
• Ng TL, O’Sullivan MJ, Pallen CJ, et al. (2007) Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. Journal of Molecular Diagnostics 9: 459–463.
• Niedan S, Kauer M, Aryee DN, et al. (2014) Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene 33: 3927–3938.
• Nishimori H, Sasaki Y, Yoshida K, et al. (2002) The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 21: 8302–8309.
• Nozawa S, Ohno T, Banno Y, et al. (2005) Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phos-pholipase D2 in Ewing sarcoma cells. The Journal of Biological Chemistry 280: 27544–27551.
• Ordóñez JL, Osuna D, Herrero D, et al. (2009) Advances in Ewing’s sarcoma research: where are we now and what lies ahead? Cancer Research 69: 7140–7150.
• Ordóñez JL, Osuna D, Garcia-Dominguez DJ, et al. (2010) The clinical relevance of molecular genetics in soft tissue sarcomas. Advances in Anatomic Pathology 17: 162–181.
• Ordóñez JL, Amaral AT, Montero-Carcaboso A, et al. PARP inhibitor olaparib enhances sensitivity of Ewing sarcoma to trabectedin (submitted).
• Pardali E, van der Schaft DW, Wiercinska E, et al. (2011) Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 30: 334–345.
• Peter M, Couturier J, Pacquement H, et al. (1997) A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 14: 1159–1164.
• Petermann R, Mossier BM, Aryee DN, et al. (1998) Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 17: 603–610.
• Pierron G, Tirode F, Lucchesi C, et al. (2012) A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nature Genetics 44: 461–466.
• Prasad SC, Thraves PJ, Bhatia KG, et al. (1990) Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing’s sarcoma cells. Cancer Research 50: 38–43.
• Prieur A, Tirode F, Cohen P, et al. (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Molecular and Cellular Biology 24: 7275–7283.
• Przybyl J, Kozak K, Kosela H, et al. (2014) Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications. Medical Oncology 31: 109.
• Qadir MA, Zhan SH, Kwok B, et al. (2014) ChildSeq-RNA: a next-generation sequencing-based diagnostic assay to identify known fusion transcripts in childhood sarcomas. Journal of Molecular Diagnostics 16: 361–370.
• Raposo G and Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. Journal of Cell Biology 200: 373–383.
• Redini F, Odri GA, Picarda G, et al. (2013) Drugs targeting the bone microenvironment: new therapeutic tools in Ewing’s sarcoma? Expert Opinion on Emerging Drugs 18: 339–352.
• Richkind KE, Romansky SG and Finklestein JZ (1996) t(4;19)(q35;q13.1): a recurrent change in primitive mesenchymaltumors? Cancer Genetics and Cytogenetics 87: 71–74.
• Riggi N, Suva ML, Suva D, et al. (2008) EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Research 68: 2176–2185.
• Riggi N, Suva ML, De Vito C, et al. (2010) EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes & Development 24: 916–932.
• Riggi N, Knoechel B, Gillespie SM, et al. (2014) EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26: 668–681. Scannell CA, Pedersen EA, Mosher JT, et al. (2013) LGR5 is expressed by Ewing sarcoma and potentiates Wnt/beta-catenin signaling. Frontiers in Oncology 3: 81.
• van der Schaft DW, Hillen F, Pauwels P, et al. (2005) Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Research 65: 11520–11528.
• Schmiedel BJ, Scheible CA, Nuebling T, et al. (2013) RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Research 73: 683–694.
• Scotlandi K, Benini S, Sarti M, et al. (1996) Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Research 56: 4570–4574.
• Scotlandi K, Manara MC, Serra M, et al. (2011) Expression of insulin-like growth factor system components in Ewing’s sarcoma and their association with survival. European Journal of Cancer 47: 1258–1266.
• Siligan C, Ban J, Bachmaier R, et al. (2005) EWS-FLI1 target genes recovered from Ewing’s sarcoma chromatin. Oncogene 24: 2512–2524.
• Smith R, Owen LA, Trem DJ, et al. (2006) Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing’s sarcoma. Cancer Cell 9: 405–416.
• Sollazzo MR, Benassi MS, Magagnoli G, et al. (1999) Increased c-myc oncogene expression in Ewing’s sarcoma: correlation with Ki67 proliferation index. Tumori 85: 167–173.
• Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. (1994) A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genetics 6: 146–151.
• Stewart E, Goshorn R, Bradley C, et al. (2014) Targeting the DNA repair pathway in Ewing sarcoma. Cell Reports 9: 829–840.
• Sumegi J, Nishio J, Nelson M, et al. (2011) A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor. Modern Pathology 24: 333–342.
• Surdez D, Benetkiewicz M, Perrin V, et al. (2012) Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-beta abolishes Ewing sarcoma growth. Cancer Research 72: 4494–4503.
• Suva ML, Riggi N, Stehle JC, et al. (2009) Identification of cancer stem cells in Ewing’s sarcoma. Cancer Research 69: 1776–1781.
• Szuhai K, Ijszenga M, de Jong D, et al. (2009) The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clinical Cancer Research 15: 2259–2268.
• Thompson L, Chang B and Barsky SH (1996) Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. The American Journal of Surgical Pathology 20: 277–285.
• Tirado OM, Mateo-Lozano S, Villar J, et al. (2006) Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing’s sarcoma cells. Cancer Research 66: 9937–9947.
• Tirode F, Surdez D, Ma X, et al. (2014) Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 4: 1342–1353.
• Torres R, Martin MC, Garcia A, et al. (2014) Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nature Communications 5: 3964.
• Tsugita M, Yamada N, Noguchi S, et al. (2013) Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles. PLoS One 8: e77416.
• Uren A, Merchant MS, Sun CJ, et al. (2003) Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing’s sarcoma cells. Oncogene 22: 2334–2342.
• Wai DH, Schaefer KL, Schramm A, et al. (2002) Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. International Journal of Oncology 20: 441–451.
• Wang L, Bhargava R, Zheng T, et al. (2007) Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. Journal of Molecular Diagnostics 9: 498–509.
• Watanabe G, Nishimori H, Irifune H, et al. (2003) Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Genes, Chromosomes & Cancer 36: 224–232.
• Wishart MJ and Dixon JE (1998) Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Trends in Biochemical Sciences 23: 301–306.
• Wysoczynski M, Liu R, Kucia M, et al. (2010) Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling. Molecular Cancer Research 8: 677–690.
• Xiong Y, Hannon GJ, Zhang H, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704.
• Yamaguchi S, Yamazaki Y, Ishikawa Y, et al. (2005) EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes, Chromosomes & Cancer 43: 217–222.
• Yang L, Hu HM, Zielinska-Kwiatkowska A and Chansky HA (2010) FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing’s sarcoma cells. Biochemical and Biophysical Research Communications 402: 129–134.
• Yasuda H, Shima N, Nakagawa N, et al. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329–1337.
• Yang Y, Zhang L, Wei Y, et al. (2008) Neural differentiation arrest in embryonal carcinoma cells with forced expression of EWS-FLI1. Journal of Neuro-Oncology 90: 141–150.
• Zanini C, Giribaldi G, Mandili G, et al. (2007) Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing’s sarcoma cell lines. Journal of Neurochemistry 103: 1344–1354.
• Zhou Z, Guan H, Duan X, et al. (2005) Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104: 1713–1720. Amaral AT, Manara MC, Berghuis D, et al. (2014) Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications. PLoS One 9: e85814.
• Antonescu C (2014) Round cell sarcomas beyond Ewing: emerging entities. Histopathology 64: 26–37.
• Crompton BD, Stewart C, Taylor-Weiner A, et al. (2014) The genomic landscape of pediatric Ewing sarcoma. Cancer Discovery 4: 1326–1341.
• Guerzoni C, Fiori V, Terracciano M, et al. (2014) CD99 triggering in Ewing sarcoma delivers a lethal Signal through p53 pathway reactivation and cooperates with doxorubicin. Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-14-0492.
• Haldar M, Hancock JD, Coffin CM, et al. (2007) A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 11: 375–388.
• Lin PP, Pandey MK, Jin F, et al. (2008) EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Research 68: 8968–8975.
• Ordóñez JL, Osuna D, Madoz-Gúrpide J and de Álava E (2015) Molecular pathology of bone and soft tissue tumors. In: Coleman WB and Tsongalis GJ, (eds). The Molecular Basis of Human Cancer, 2nd edn. Totowa, NJ: Humana Press.
• Sainz-Jaspeado M, Huertas-Martinez J, Lagares-Tena L, et al. (2013) EphA2-induced angiogenesis in Ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS One 8: e71449.
• Schmiedel BJ, Scheible CA, Nuebling T, et al. (2013) RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Research 73: 683–694.
• Scotlandi K and Picci P (2008) Targeting insulin-like growth factor 1 receptor in sarcomas. Current Opinion in Oncology 20: 419–427.
• Torchia EC, Boyd K, Rehg JE, et al. (2007) EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Molecular and Cellular Biology 27: 7918–7934.